Compare PDT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDT | IRWD |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.7M | 520.6M |
| IPO Year | N/A | 2010 |
| Metric | PDT | IRWD |
|---|---|---|
| Price | $12.84 | $5.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.74 |
| AVG Volume (30 Days) | 145.6K | ★ 7.4M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 8.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.22 |
| P/E Ratio | ★ N/A | $30.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.77 | $0.53 |
| 52 Week High | $13.05 | $5.78 |
| Indicator | PDT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 71.76 |
| Support Level | $12.74 | $4.17 |
| Resistance Level | $12.97 | $5.57 |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 64.86 | 80.53 |
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest capital growth. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.